{"Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0.5 and is expected to have higher plasma concentrations of flurbiprofen which may increase the risk of toxicities. Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Dose titration should not occur until after steady state is reached (at least 5 days for flurbiprofen). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo. Please consult a clinical pharmacist for more information."}